BA-Merrill Lynch 11/01/2010 1 Buy, Medium Risk $38.90 21.9%
The broker notes IVIG volume growth in the US in October and November was somewhat soft, though it suggests upcoming results from Baxter late this month will provide a better insight into the market.
On the plus side growth in Factor VIII in November was good and the broker sees this as a positive given it is a more expensive product and is an important growth driver for the company in its view.
Leading into the company's interim result next month the broker retains its Buy rating, supported by a new fractionation agreement the company has signed in the Australian market.
BA-Merrill Lynch 11/01/2010 1 Buy, Medium Risk $38.90 21.9%The...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$305.47 |
Change
1.060(0.35%) |
Mkt cap ! $148.3B | |||
| Open | High | Low | Value | Volume |
| $303.88 | $307.33 | $303.80 | $141.3M | 462.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 750 | $305.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $305.53 | 1372 | 3 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |